$3.68
11.18% day before yesterday
Nasdaq, Dec 27, 10:14 pm CET
ISIN
US17322U2078
Symbol
CTXR
Sector
Industry

Citius Pharmaceuticals Inc Stock price

$3.68
+0.08 2.22% 1M
-12.28 76.94% 6M
-15.23 80.54% YTD
-16.05 81.35% 1Y
-36.82 90.91% 3Y
-23.32 86.37% 5Y
-386.32 99.06% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.37 11.18%
ISIN
US17322U2078
Symbol
CTXR
Sector
Industry

Key metrics

Market capitalization $28.44m
Enterprise Value $29.47m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.31
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-42.00m
Free Cash Flow (TTM) Free Cash Flow $-28.20m
Cash position $3.25m
EPS (TTM) EPS $-5.95
P/E forward 3.02
P/S forward 0.72
EV/Sales forward 0.74
Short interest 7.00%
Show more

Is Citius Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Citius Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Citius Pharmaceuticals Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Citius Pharmaceuticals Inc forecast:

Buy
67%
Hold
33%

Financial data from Citius Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.21 0.21
11% 11%
-
-0.21 -0.21
11% 11%
-
- Selling and Administrative Expenses 30 30
38% 38%
-
- Research and Development Expense 12 12
20% 20%
-
-42 -42
14% 14%
-
- Depreciation and Amortization 0.21 0.21
11% 11%
-
EBIT (Operating Income) EBIT -42 -42
14% 14%
-
Net Profit -39 -39
20% 20%
-

In millions USD.

Don't miss a Thing! We will send you all news about Citius Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Citius Pharmaceuticals Inc Stock News

Neutral
PRNewsWire
one day ago
Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended S...
Neutral
PRNewsWire
about one month ago
CRANFORD, N.J. , Nov. 25, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that the Company held a constructive in-person Type C meeting with the U.S. Food and Drug Administration (FDA).
Neutral
PRNewsWire
about one month ago
CRANFORD, N.J. , Nov. 22, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 ("Reverse Stock Split").
More Citius Pharmaceuticals Inc News

Company Profile

Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of hemorrhoids. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Head office United States
CEO Leonard Mazur
Employees 23
Founded 2007
Website www.citiuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today